The response of plasma immunoreactive insulin (IRI), free fatty acids (FFA), and blood glucose to intravenous (I.V.) glucagon is evaluated in ten healthy subjects and in 22 patients following acute myocardial infarction (MI). Heparinized venous blood samples were drawn from patients and subjects in the fasting state and 2, 5, 15, 30, 60, 90, and 120 min after 1 mg I.V. glucagon. Healthy subjects showed a significant increase in insulin (peak at 5 min) and blood glucose (peak 15 min), and a persistent fall in FFA (nadir 90 min). In patients in the first week after suffering an acute MI, there was a significant elevation in fasting blood glucose whereas fasting insulin was low and FFA, normal. After glucagon administration, there was a pronounced rise in insulin and a significant rise in glucose and FFA. Six weeks after the acute MI, the mean fasting blood glucose reading showed a fall whereas insulin rose to normal range. Glucagon elicited a rise in insulin, glucose, and FFA. These results suggest that after MI the insulin resistance is a stronger influence than failure of insulin secretion. The relevance of these results in relation to use of glucagon in large doses in cardiogenic shock of MI is discussed.
Additional Indexing Words:
Immunoreactive insulin Ischemic heart disea IABETES MELLITUS and ischemic heart disease (IHD) are causally related. IHD and accelerated IHD are major complications of diabetes mellitus.A4 In addition, increased frequency of abnormal carbohydrate tolerance in IHD has also been extens.ively reported.-6 The reasons for the latter observation are now well understood. Both increased and decreased insulin secretion, as well as delayed secretion, after oral or intravenous. glucose load in IHD have been documented.0 10 Hemodynamic1" and neurohumoral'0' 12 disturbances associated with myocardial infarction (MI) can influence the glucose tolerance, and the recent report that glucose tolerance and insulin secretion are also deranged in nonischemic cardiovascular disease,'3 has made it difficult to evaluate to what extent these abnormalities are related to the pathogenesis of IHD. Glucagon, a pancreatic polypeptide hormone, has been shown to have inotropic and chronotropic effects on the myocardium in animals14 and humans.15 It has also been used successfully in massive doses for the treatment of shock following MI.16 Since glucagon is a potent stimulator of insulin secretion17 and actively mobilizes energy-providing substrates,18 the present study was undertaken to study the changes in blood glucose, plasma free fatty acids (FFA), and immunoreactive insulin (IRI) following intravenous (I.V.) glucagon administration in patients with acute MI.
Material and Methods
All patients included in the study had clinical and electrocardiographic evidence of acute myocardial infarction. They were studied in the first week, usually between the fourth and seventh day after occurrence of MI, and in those available, the test was repeated in the seventh week. They were all stable and free from significant ventricular arrhythmias, pulmonary congestion, and hypotension. None of them was obese (weight within + 15% of ideal body weight according to Metropolitan Life Insurance tables), a known diabetic, or had knowledge of diabetes in parents or siblings. 357 They were also not receiving xylocaine, heparin, or other therapy had been stopped for 48 hours before testing. Tlhev were also not receiving xylocaine, heparin, or other drugs known to affect carbohydrate or lipid metabolism. The control subjects matched in age, sex, and weight were drawn from patients' friends or relations or hospital personnel. Their clinical and electrocardiographic examination did not reveal IHD or any other illniess kinown to inifluence carbohydrate metabolism.
It was determined that patients and normal subjects were taking at least 300 g of carbohydrates in their diets for at least two days prior to the glucagon test. After an overnight fast, patients and subjects were prepared by placing an indwelling needle in one of the antecubital veins and kept patent by heparinized saline. A fasting venous blood sample was drawn and 1 mg glucagon (Eli Lilly) was injected over 30 sec into the other antecubital vein. Further blood samples were obtained after 2, 5, 15, 30, 60, 90, and 120 min. Each sample was analyzed for glucose,19 plasma FFA,20 and IRI.2' The first two estimations were completed the same day and plasma was stored at -20°C for IRI assay. Samples from a patient from the first and second test were measured in the same insulin assay.
Results
A total of 22 patients and ten normal subjects were studied. In 19 patients the test could be repeated after six weeks. None of them had gained weight during this period. There were 21 men and only one woman, their ages ranged from 35 to 60 years with a mean of 45. Ten men with mean age 41 years (range 35-60 years) constituted the control group. The fasting blood glucose in normal subjects at 69 mg/ 100 ml + 4 (SEM) was significantly lower (P < 0.01) than that in patients with MI either in the first week (92 + 5.2) or in the seventh week (88 + 4.8). There was rapid increase in blood glucose following glucagon administration and peak was observed at 15 min ( fig. 1 ). The mean maximal rise over fasing level in normal subjects at 16 mg/ 100 ml ± 4.5 was significantly (P<0.05) less than that in MI patients tested in the first (29 + 4.5) or the seventh week (40.2 ± 10). Figure 2 shows the plasma IRI response in the three groups. Fasting mean plasma IRI in MI patients in the first week (10 ,gunits/ml ± 0.9) was significantly (P < 0.01) lower than the control group of MI patients when tested in the seventh week. A brisk rise in the plasma IRI in all three groups was evident, with peak at 5 min. The mean maximal rise over the fasting level in MI patients in the first week at 61.4 gU/ml + 7.7 was significantly (P < 0.05) greater than that in the other two groups.
The mean fasting plasma FFA in the three groups did not differ significantly (P > 0.05). However, the response in normal subjects was tests showed an initial rise. There was subsequently a fall in FFA level, but values did not fall significantly below the fasting level ( fig. 3 ).
Discussion
The present results utilizing a different stimulus for glucose and insulin secretion confirm earlier reports based on glucose tolerance tests that carbohydrate and lipid metabolism are deranged in patients with acute myocardial infarction.6-9 These abnormalities were evident not only in the acute phase but persisted even six weeks after the acute episode. The IRI secretion in patients with MI was either enhanced or comparable to that of normal subjects in response to glucagon, yet in these patients a significantly higher glucose level was observed after glucagon administration in both the first and seventh week. The antagonism to insulin in these patients, which could be explained either by rising FFA levels or by some other hitherto ill-understood mechanism, could account for the abnormal rise in blood glucose. In MI patients a rise in FFA concentration, rather than a fall as seen in normal subjects, is a further indication of insulin antagonism. Although glucagon has a potent lipolytic effect,22 the concomitant rise in insulin and glucose are normally able to effectively suppress the lipolysis. However, either an enhanced sensitivity to lipolytic effect of glucagon or antagonism to circulating insulin can Plasma free fatty acids (FFA) response to 1 mg I.V. glucagon in control subjects and patients following myocardial infarction.
Circulation, Volume XLIX, February 1974 explain the abnormal behavior of FFA. This observation could be taken to suggest that subjects with myocardial infarction have easy mobilization of FFA. Increased FFA availability could be a source for increased circulating triglycerides and lipoproteins from the liver23-26 as well as enhanced lipid deposition in the myocardium and other tissues27 and thus be causally related to the development of IHD.
In the normally oxygenated myocardium both glucose and FFA are major sources of energy.28 Opie,29 in a review of metabolic response during impending myocardial infarction, has considered the animal data and summarized that to an ischemic myocardium glucose is beneficial and FFA harmful. High circulating levels of FFA have also been correlated with both high mortality in acute MI30 and a high incidence of arrhythmias.30' 31 The latter postulate has been denied. 32 The recent renewed interest in the use of glucose, insulin, and potassium in the treatment of cardiogenic shock33 has grown out of these findings. Glucagon has also been used in massive doses to treat cardiogenic shock.'6 The results of present investigations have revealed that glucagon administration, even in a small dose of 1 mg, mobilizes glucose and stimulates insulin secretion. There is every likelihood that massive doses of glucagon, up to 250 mg/24 hr, the dose commonly administered for cardiogenic shock, would have much more pronounced effect on glucose and insulin levels. Since glucose and insulin are beneficial to ischemic myocardium,29 these metabolic effects of glucagon could theoretically complement the drug's direct cardiotonic effect through activation of the cyclic AMP mechanism.'6 However, the rise in plasma FFA following intravenous glucagon as observed in MI patients in this study does indicate a word of caution for the routine use of high doses of glucagon in the treatment of cardiogenic shock as raised FFA levels have been conclusively shown to be associated with mortality in acute MI.30 Further investigations on plasma FFA levels under these circumstances are necessary. 
